Abstract
Despite historical controversy, pharmacologic ascorbate is emerging as promising cancer therapy via pro-oxidant chemistry. In this issue of Cancer Cell, Schoenfeld etal. describe how intracellular iron pools and reactive oxygen species drive pharmacologic ascorbate's selective toxicity to cancer cells invitro, in mice, and in humans.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
